Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
PP&E Net
Editas Medicine Inc
PP&E Net Peer Comparison
Competitive PP&E Net Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
PP&E Net
$44.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Net
$5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Net
$5.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Net
$1.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Net
$4.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
22%
|
See Also
What is Editas Medicine Inc's PP&E Net?
PP&E Net
44.7m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's PP&E Net amounts to 44.7m USD.
What is Editas Medicine Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
11%
Over the last year, the PP&E Net growth was -10%. The average annual PP&E Net growth rates for Editas Medicine Inc have been 1% over the past three years , 11% over the past five years .